Serum testosterone and prostate cancer in men with germline BRCA1/2 pathogenic variants

Serum testosterone and prostate cancer in men with germline BRCA1/2 pathogenic variants

Abstract Objectives The relation of serum androgens and the development of prostate cancer (PCa) is subject of debate. Lower total testosterone (TT) levels have been associated with increased PCa detection and worse pathological features after treatment. However, data from the Reduction by Dutasteri...

Full description

Bibliographic Details
Main Authors: Alexander Dias, Mark N. Brook, Elizabeth K. Bancroft, Elizabeth C. Page, Anthony Chamberlain, Sibel Saya, Jan Amin, Christos Mikropoulos, Natalie Taylor, Kathryn Myhill, Sarah Thomas, Edward Saunders, Tokhir Dadaev, Daniel Leongamornlert, Thomas Dyrsø Jensen, D. Gareth Evans, Cezary Cybulski, Annelie Liljegren, Soo H. Teo, Lucy Side, The IMPACT study collaborators and Steering Committee, Zsofia Kote‐Jarai, Rosalind A. Eeles
Format: Article
Language:English
Published: Wiley 2023-05-01
Series:BJUI Compass
Subjects:
androgens
biomarkers
BRCA1/BRCA2 pathogenic variant
prostate cancer
testosterone
Online Access:https://doi.org/10.1002/bco2.156

Similar Items

Similar Items